Oncology Medical News about amrubicinol

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities
Anti-Cancer Drugs, 07/02/09

Tochino Y et al. - The plasma concentration of AMR-OH on day 4 was correlated with hematological toxicities in patients treated with AMR. The assessment of plasma concentration of AMR-OH at one timepoint might enable the prediction of hematological toxicities.

<< Previous
Analysis of the Ten-Eleven Translocation (TET)2 gene in familial...

Next >>
Nitroimidazole-based bioreductive compounds bearing a quinazoline...

Today in Pharmacology/Therapy...keeping you current

Radiotherapy in the Treatment of Resectable Rectal Adenocarcinoma
American Journal of Clinical Oncology, 12/07/09

Solitary Plasmacytoma
American Journal of Clinical Oncology, 12/07/09

Total Cystectomy Versus Bladder Preservation Therapy for Locally Invasive Bladder Cancer: Effect of Combined Therapy Using Balloon-Occluded Arterial Infusion of Anticancer Agent and Hemodialysis With Concurrent Radiation
American Journal of Clinical Oncology, 12/07/09

See all of Pharmacology/Therapy